BDSX · Biodesix Inc
$22.22
+0.13 (+0.57%)
At close · Jul 27
Market Cap
$222.39M
Shares
10.11M
Biodesix Inc Earnings Call Transcripts
Every quarterly earnings call for Biodesix Inc (BDSX) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲70.1%
$11.11M
−$13.70M
'22 Q3
22-10-11
▲33%
$9.61M
−$20.34M
'22 Q4
23-03-06
▲38.3%
$9.06M
−$18.70M
'23 Q1
23-05-11
▲8.4%
$11.87M
−$13.36M
'23 Q2
23-08-07
▲21.5%
$13.49M
−$10.95M
'23 Q3
23-11-07
▲52.7%
$14.67M
−$9.14M
'23 Q4
24-03-01
▲63.6%
$14.82M
−$13.61M
'24 Q1
24-05-08
▲51%
$17.93M
−$10.81M
'24 Q2
24-08-07
▲34.5%
$18.15M
−$10.26M
'24 Q3
24-11-01
▲39.3%
$20.43M
−$8.25M
'24 Q4
25-01-10
▲21.2%
$17.96M
−$11.10M
'25 Q1
25-05-13
▲11.7%
$20.02M
−$11.47M
'25 Q2
25-08-07
▲19.9%
$21.77M
−$8.72M
'25 Q3
25-11-03
▲40.8%
$28.75M
−$3.98M
'25 Q4
26-02-26
LATEST
▲42.3%
$25.55M
−$7.79M
'26 Q1
26-05-04
Earnings call
FY26 · Q2
2026-08-05
Biodesix Q2 2026 Earnings Conference Call
Scheduled
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
William Blair 46th Annual Growth Stock Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-04
Biodesix Inc Q1 FY2026 Earnings Call
Confident tone
Lung Diagnostic Testing Growth
Profitability and Operating Leverage
Development Services / Biopharma
Revenue
$25.55M
▲ 42.3% YoY Diluted EPS
$-0.81
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Biodesix Inc Q4 FY2025 Earnings Call
Confident tone
Lung Diagnostics Growth
HEDIS / Lung Cancer Screening Guidelines
Profitability Milestones
Revenue
$28.75M*
▲ 40.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-03
Biodesix Inc Q3 FY2025 Earnings Call
Confident tone
Lung diagnostics / Nodify testing
Sales force productivity and expansion
Revenue and margin growth
Revenue
$21.77M
▲ 19.9% YoY Diluted EPS
$-1.16
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Biodesix Inc Q2 FY2025 Earnings Call
Positive tone
Lung nodule diagnostic commercial expansion
Primary care sales strategy
Development Services / biopharma
Revenue
$20.02M
▲ 11.7% YoY Diluted EPS
$-1.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Biodesix Inc Q1 FY2025 Earnings Call
Positive tone
Primary Care Commercial Expansion
Sales Team Reconfiguration
Lung Diagnostics Growth (Nodify)
Revenue
$17.96M
▲ 21.2% YoY Diluted EPS
$-1.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-10
Biodesix Inc Q4 FY2024 Earnings Call
Positive tone
Lung disease market opportunity
Clinical studies and evidence generation
Diagnostic development services / biopharma
Revenue
$20.43M*
▲ 39.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-01
Biodesix Inc Q3 FY2024 Earnings Call
Positive tone
Sales team expansion and productivity
Lung diagnostic test growth and adoption
Hurricane impact on Q3 operations
Revenue
$18.15M
▲ 34.5% YoY Diluted EPS
$-1.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Biodesix Inc Q2 FY2024 Earnings Call
Confident tone
Lung diagnostic test growth and volume
Revenue guidance raise and financial performance
Operational efficiency and facilities
Revenue
$17.93M
▲ 51% YoY Diluted EPS
$-1.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Biodesix Inc Q1 FY2024 Earnings Call
Confident tone
Lung Diagnostic test volume growth
Gross margin expansion
Path to profitability / adjusted EBITDA
Revenue
$14.82M
▲ 63.6% YoY Diluted EPS
$-2.80
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-01
Biodesix Inc Q4 FY2023 Earnings Call
Confident tone
Lung diagnostic test volume growth
Biopharmaceutical services
Sales force expansion
Revenue
$14.67M*
▲ 52.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Biodesix Inc Q3 FY2023 Earnings Call
Revenue
$13.49M
▲ 21.5% YoY Diluted EPS
$-2.80
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-07
Biodesix Inc Q2 FY2023 Earnings Call
Revenue
$11.87M
▲ 8.4% YoY Diluted EPS
$-3.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Biodesix Inc Q1 FY2023 Earnings Call
Revenue
$9.06M
▲ 38.3% YoY Diluted EPS
$-4.80
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-06
Biodesix Inc Q4 FY2022 Earnings Call
Revenue
$9.61M*
▲ 33% YoY
Rev · 7q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-10-11
Biodesix Inc Q3 FY2022 Earnings Call
Revenue
$11.11M
▲ 70.1% YoY Diluted EPS
$-6.80
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Biodesix Inc Q2 FY2022 Earnings Call
Revenue
$10.95M
▼ 7.9% YoY
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-11
Biodesix Inc Q1 FY2022 Earnings Call
Revenue
$6.55M
▼ 77.3% YoY
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-14
Biodesix Inc Q4 FY2021 Earnings Call
Revenue
$7.22M*
Rev · 4q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-15
Biodesix Inc Q3 FY2021 Earnings Call
Revenue
$6.53M
▼ 29% YoY
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-10
Biodesix Inc Q2 FY2021 Earnings Call
Revenue
$11.88M
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-11
Biodesix Inc Q1 FY2021 Earnings Call
Revenue
$28.87M
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Showing 1–23 of 23 earnings calls